Human Milk Oligosaccharides for Infant Inflammation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current infant formulas lack effective means to modulate inflammation and enhance immunity against microbial infections, particularly in preterm and term infants, where unregulated inflammation can lead to tissue damage and clinical diseases due to the immaturity of their immune systems.
Innovation Solution
Development of synthetic infant, pediatric, and child formulas incorporating human milk oligosaccharides (HMOs) such as 3′-sialyllactose, 6′-sialyllactose, and lacto-N-neotetraose, combined with long chain polyunsaturated fatty acids and antioxidants, to reduce inflammation and enhance immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If infant formulas use conventional nutritional components, then basic nutrition is provided, but inflammation modulation and immune enhancement are insufficient
Solution Approach 1:
The patent combines multiple HMOs (3'-sialyllactose, 6'-sialyllactose, lacto-N-neotetraose) with long chain polyunsaturated fatty acids and antioxidants to create a composite nutritional composition that provides synergistic anti-inflammatory and immune-enhancing effects, resolving the limitation of conventional single-component formulas
Solution Approach 2:
The patent specifies precise concentration ranges for each HMO component (e.g., 3'-sialyllactose at 0.001-20 mg/mL, 6'-sialyllactose at 0.001-20 mg/mL, lacto-N-neotetraose at 0.001-0.2 mg/mL) to optimize anti-inflammatory activity while ensuring safety and efficacy in modulating infant immune responses
2Reliability
If HMO concentrations are increased to enhance immune modulation, then inflammation control improves, but formulation complexity and manufacturing difficulty increase
Solution Approach 1:
The patent uses low concentrations of specific HMOs (e.g., lacto-N-neotetraose at 0.001-0.2 mg/mL) that provide sufficient anti-inflammatory activity without requiring high doses, thereby simplifying manufacturing while maintaining therapeutic efficacy
Solution Approach 2:
By defining specific concentration ranges for each HMO component, the patent optimizes the balance between anti-inflammatory efficacy and manufacturing feasibility, allowing standard formulation processes to be used while achieving reliable inflammation control
Data Source
AI summary
Disclosed are nutritional compositions including human milk oligosaccharides that can be administered to preterm infants, term infants, toddlers, and children for reducing inflammation and the incidence of inflammatory diseases.